Mode
Text Size
Log in / Sign up

Stepwise energy escalation ESWL showed higher stone-free rates than fixed-energy protocols in pediatric urolithiasis.

Stepwise energy escalation ESWL showed higher stone-free rates than fixed-energy protocols in pediat…
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider stepwise energy escalation in pediatric ESWL, but await prospective multicenter confirmation before changing practice.

This retrospective cohort study evaluated 81 children treated with extracorporeal shock wave lithotripsy (ESWL) for pediatric urolithiasis at a single center. Participants were assigned to either a stepwise energy protocol, which began at 10 kV and increased by 1 kV every 250 shocks up to 13 kV with a maximum of 3,000 shocks per session, or a conventional fixed-energy protocol utilizing a constant 13 kV setting.

Primary analysis assessed 3-month stone-free status, defined as no visible stones on follow-up imaging excluding fragments less than or equal to 3 mm. Secondary outcomes included stone-free status after the first session, total number of sessions, and the need for auxiliary procedures. At three months, 95.1% (39/41) of patients in the stepwise group achieved stone-free status compared to 87.5% (35/40) in the conventional group. Stone clearance at three months, including fragments less than or equal to 3 mm, was 97.6% (40/41) versus 95.0% (38/40). Additionally, 30 children in the stepwise group achieved clearance in a single session compared to 22 in the conventional group.

Safety and tolerability were assessed through reported adverse events. Only minor, self-limited events such as hematuria and transient pain or colic were observed. One case of auxiliary ureteroscopy was required in the stepwise group versus two in the conventional group. No serious adverse events or discontinuations were reported.

Key limitations include the retrospective design, single-center setting, and limited pediatric evidence base. Statistical significance was not reported for the observed differences. While stepwise energy escalation was associated with numerically higher clearance and fewer sessions without added morbidity, causality cannot be inferred. Prospective multicenter studies are needed to confirm these findings before changing clinical practice.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
BackgroundPediatric extracorporeal shock wave lithotripsy (ESWL) is widely used, but the optimal energy-delivery strategy remains uncertain. Adult data suggest that stepwise energy escalation may enhance fragmentation and limit tissue injury; pediatric evidence is limited.MethodsWe conducted a single-center retrospective cohort of 81 children treated with ESWL using either a stepwise energy protocol (n = 41) or a conventional fixed-energy protocol (n = 40). The stepwise protocol began at 10 kV with 1 kV increases every 250 shocks up to 13 kV (maximum 3,000 shocks per session); the conventional protocol used a fixed 13 kV. Primary outcome was 3-month stone-free status, defined as no visible stones on follow-up imaging, excluding fragments ≤3 mm. Secondary outcomes included stone-free status after the first session, number of sessions, auxiliary procedures, and complications.ResultsAfter the first session, stone-free status was observed in 73.2% (30/41) with the stepwise protocol vs. 55.0% (22/40) with the conventional protocol. At 3 months, rates were 95.1% (39/41) vs. 87.5% (35/40). When fragments ≤3 mm were considered clearance, overall rates were 97.6% (40/41) vs. 95.0% (38/40). More children achieved clearance in a single session with the stepwise protocol (30 vs. 22). Auxiliary ureteroscopy was required in 1 vs. 2 cases. Only minor, self-limited events (hematuria, transient pain/colic) were reported.ConclusionStepwise energy escalation was associated with numerically higher clearance and fewer sessions than fixed-energy ESWL, without added morbidity. Prospective multicenter studies are needed to confirm these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.